Earlier this month, Roche’s Tecentriq (atezolizumab) gained FDA approval as first-line monotherapy to treat metastatic non-small cell lung cancer (NSCLC), becoming the fourth approval in the indication, as well as the fifth approval in lung cancer as a whole.

The approval comes from data of the Phase III Impower110 trial, which concluded an overall survival benefit in patients with high PD-L1 expression. Read more here.